

REMARKS

The Abstract of the Disclosure is hereby submitted on a separate sheet of paper. The claims have been amended to cancel claims 34-49. No new matter has been introduced. Claims 1-33 are pending in this application. Claims 34-49 have been canceled.

Conclusion

Entry of the above amendments is earnestly solicited. An early and favorable first action on the merits is earnestly solicited.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact MaryAnne Armstrong (Reg. No. 40,069) at the telephone number of the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.

Application No.: Not Yet Assigned

Docket No.: 1912-0308PUS1

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37.C.F.R. §§1.16 or 1.14; particularly, extension of time fees.

Dated: April 22, 2005

Respectfully submitted,

MAA/clb

By ma au

MaryAnne Armstrong

Registration No.: 40,069

BIRCH, STEWART, KOLASCH & BIRCH, LLP

8110 Gatehouse Rd

Suite 100 East

P.O. Box 747

Falls Church, Virginia 22040-0747

(703) 205-8000

Attorney for Applicant

ABSTRACT OF THE INVENTION

The present invention relates to a method to stimulate reversal of a diabetic state in a patient; a method to prevent autoimmune destruction of new insulin-producing cells (pancreatic beta-cells) in a patient; a method to promote survival of the newly regenerated insulin-producing cells (pancreatic beta-cells); and an *in vivo* method for the induction of islet cell neogenesis and new islet formation and the prevention of autoimmune destruction of said new cells.